BCIM
CRL icon

British Columbia Investment Management’s Charles River Laboratories CRL Stock Holding History

British Columbia Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,885
Closed -$1.82M – 712
2024
Q4 		$1.82M Buy
9,885
+1,291
+15% +$249K 0.01% 643
2024
Q3 		$1.69M Sell
8,594
-1,240
-13% -$258K 0.01% 640
2024
Q2 		$2.03M Sell
9,834
-41,290
-81% -$9.36M 0.01% 606
2024
Q1 		$13.9M Buy
51,124
+224
+0.4% +$53.5K 0.1% 155
2023
Q4 		$12M Buy
50,900
+1,267
+3% +$249K 0.1% 160
2023
Q3 		$9.73M Buy
49,633
+4,000
+9% +$821K 0.09% 153
2023
Q2 		$9.59M Buy
45,633
+93
+0.2% +$18.5K 0.09% 169
2023
Q1 		$9.19M Buy
45,540
+66
+0.1% +$15K 0.1% 185
2022
Q4 		$9.91M Buy
45,474
+10,450
+30% +$2.28M 0.11% 168
2022
Q3 		$6.89M Buy
35,024
+7,789
+29% +$1.68M 0.08% 215
2022
Q2 		$5.83M Sell
27,235
-4,956
-15% -$1.21M 0.06% 268
2022
Q1 		$9.14M Sell
32,191
-9,066
-22% -$2.8M 0.06% 264
2021
Q4 		$15.5M Sell
41,257
-3,429
-8% -$1.33M 0.09% 199
2021
Q3 		$18.4M Sell
44,686
-18,559
-29% -$7.71M 0.11% 160
2021
Q2 		$23.4M Buy
63,245
+9,345
+17% +$3.12M 0.14% 129
2021
Q1 		$15.6M Sell
53,900
-6,200
-10% -$1.72M 0.11% 173
2020
Q4 		$15M Sell
60,100
-7,500
-11% -$1.79M 0.11% 159
2020
Q3 		$15.3M Sell
67,600
-5,400
-7% -$1.12M 0.13% 138
2020
Q2 		$12.7M Buy
73,000
+27,300
+60% +$4.36M 0.13% 144
2020
Q1 		$5.77M Buy
45,700
+24,400
+115% +$3.66M 0.1% 185
2019
Q4 		$3.25M Buy
+21,300
New +$2.95M 0.02% 502

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

British Columbia Investment Management's CRL Position: Q1 2025 in Review

British Columbia Investment Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 9,885 shares — an estimated $1.82M sold.

British Columbia Investment Management first reported a position in CRL in Q4 2019 and held it in 21 quarters. The position peaked at $23.4M in Q2 2021. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • British Columbia Investment Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • British Columbia Investment Management sold 9,885 Charles River Laboratories shares in Q1 2025, an estimated $1.82M.
  • British Columbia Investment Management first reported a position in Charles River Laboratories in Q4 2019 and held it in 21 quarters.
  • British Columbia Investment Management's Charles River Laboratories position peaked at $23.4M in Q2 2021.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on British Columbia Investment Management's 13F filing for Q1 2025, filed 14 May 2025.